Cardiovascular Disease

ADVENT Trial: Pulse Field Ablation for AFib

The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More

Target-HTN trial: Lorundrostat in Hypertension

The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More

OCTOBER Trial: OCT in Complex PCI

The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More

LODESTAR Trial: Statin and CAD

The LODESTAR trial, as featured in JAMA in 2023, was a randomized, multicenter, noninferiority trial focusing on coronary artery disease (CAD) treatment strategies. The objective was to assess whether a treat-to-target strategy for low-density lipoprotein cholesterol (LDL-C) is noninferior to … Read More

HEART-FID Trial: Iron in Heart Failure

The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More

FIRE Trial: Complete PCI in MI in Older Patients

The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More

ECLS-SHOCK Trial: Extracorporeal Life Support in Cardiogenic Shock

The ECLS-SHOCK trial, as reported in the New England Journal of Medicine in 2023, was a multicenter, parallel, randomized controlled trial designed to evaluate the efficacy of extracorporeal life support (ECLS) in patients with acute myocardial infarction (MI) complicated by … Read More

RADIANCE-HTN TRIO Trial: Renal Denervation in HTN

The RADIANCE-HTN TRIO trial, detailed in The Lancet in 2021, is another pivotal study in the domain of hypertension treatment, focusing on a challenging group of patients: those resistant to a standard triple combination pill. This trial delves into the … Read More

SELECT Trial: Semaglutide and CV outcomes

Semaglutide Improve CV events? SELECT Trial Summary The SELECT trial, a pivotal study published in the New England Journal of Medicine (NEJM) in November 2023, has offered the medical community valuable insights into the treatment of cardiovascular (CV) events in … Read More

ORBITA-2 Trial: PCI in Stable Angina

Understanding the Impact of PCI in Stable Angina: Insights from the ORBITA-2 Trial The ORBITA-2 trial has emerged as a cornerstone study in the field of cardiology, particularly in the treatment of stable angina through Percutaneous Coronary Intervention (PCI). This … Read More